BIIB34:BVMF
Biogen Inc BDR
184,49Â R$
0,00%
(0,00) 1K
5-okt, 16:56:00 (GMT-3) · BRL
search
Barcha belgilar
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoBIIB34 tikeri uchun statistika yaratilmoqda...
Ochish
185,82Â R$
Yuqori
185,82Â R$
Past
184,49Â R$
Bozor kapitali
33,04Â mlrd
Oʻrtacha hajm
1,00
Hajmi
185,00
52 haftalik eng yuqori
191,00Â R$
52 haftalik eng past
128,69Â R$
Muomaladagi aksiyalar
147,75Â mln
Xodimlar soni
8Â ming
Ochish
185,82Â R$
Yuqori
185,82Â R$
Past
184,49Â R$
Bozor kapitali
33,04Â mlrd
Oʻrtacha hajm
1,00
Hajmi
185,00
52 haftalik eng yuqori
191,00Â R$
52 haftalik eng past
128,69Â R$
Muomaladagi aksiyalar
147,75Â mln
Xodimlar soni
8Â ming
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
Kalkine Media
·
9 soat oldin
Biogen's Chief Accounting Officer Sean Godbout Reports October 2026 Stock Transactions via Form 4
AD HOC NEWS
·
11 soat oldin
Biogen stock gains 1.56 percent as litifilimab data reach Week 52
Profil
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
Biogen Inc BDR haqida
CEOChris Viehbacher
Xodimlar soni7,5Â ming
Asos solingan1978
Bosh ofislarKembrij, Massachusetts, Amerika Qo‘shma Shtatlari
Sektor-
Veb-saytbiogen.com